Vimarsana
Biggest News Aggregation in the World

Page 3 - Unrolling News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Unrolling. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Unrolling Today - Breaking & Trending Today

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

–Multiple vepdegestrant studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib... | May 5, 2023

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Vimarsana News

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease ; topline results expected 2Q 2023 SHINE trial currently enrolling patients with first patient in Spain... | May 4, 2023

NuLegacy Gold Improves Discovery Prospects - Vimarsana News

NuLegacy Gold Improves Discovery Prospects

Enrolls Robert LeonardsonRENO, Nev., April 11, 2023 -- NuLegacy Gold is pleased to report enrolling the renowned Mr. Robert Leonardson, BSGE, MSG, Michigan Tech thus adding another member of the... | April 11, 2023

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma - Vimarsana News

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 -- Caribou Biosciences, Inc. , a leading clinical-stage CRISPR... | April 4, 2023

Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) - Vimarsana News

Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

U.S. Food & Drug Administration approves enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with... | March 27, 2023